CASTLE BIOSCIENCES, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CASTLE BIOSCIENCES, INC. (CSTL) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $607.00K, a 4235.71% increase year-over-year.
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $4.69M, a 672.16% increase from fiscal 2024.
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $607.00K, a 60.76% decline from fiscal 2023.
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.55M, a 74.53% decline from fiscal 2022.
- CASTLE BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $6.08M, a 110.06% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 | |||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $4.69M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $4.69M 10-Q · filed 2025-11-03 | ||||
| 2025-06-30 | $4.69M 10-Q · filed 2026-07-30 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $607.00K derived: sum of 2 quarters · filed 2026-02-26 | $607.00K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $607.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $607.00K 10-Q · filed 2025-11-03 | ||||
| 2024-08-01 | $600.00K 10-K · filed 2025-02-27 | |||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-04 | |||||
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.06M derived: sum of 2 quarters · filed 2026-02-26 | $1.55M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $499.00K 10-Q · filed 2024-11-04 | ||||
| 2023-06-30 | $485.00K 10-Q · filed 2024-08-05 | |||||
| 2022-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.08M derived: sum of 2 quarters · filed 2025-02-27 | $6.08M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $5.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.91M 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | |||||
| 2021-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.89M 10-K · filed 2023-02-28 | $2.90M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $427.00K 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |